Two Patents for Use of Dyax' DX-88 in cardiothoracic surgery
Dyax Corp. announced that the United States Patent and Trademark office has issued two U.S. patents relating to its program for on-pump cardiothoracic surgery (CTS). U.S. Patent No. 7,153,829 (issued December 26, 2006) covers methods for preventing or reducing perioperative blood loss due to surgery by administering its proprietary kallikrein inhibitor, DX-88 (ecallantide), as well as methods for preventing or reducing reperfusion injury with DX-88. U.S. Patent No. 7,064,107 covers methods for preventing or reducing ischemia or systemic inflammatory response associated with surgery by administering a kallikrein inhibitor. The new patents provide Dyax with claims that directly cover the company's CTS program.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.